Warning Letter Record: Spa De Soleil, Inc. (2026-07-08) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Key takeaway: The FDA issued a warning letter (320-26-100) to Spa De Soleil, Inc. on July 8, 2026, following a January 20-26, 2026 inspection, citing CGMP violations for finished OTC pharmaceuticals at its Sun Valley, California facility. The FDA found the firm failed to adequately investigate 51 out-of-limit/out-of-specification results from its water system between May 2024 and July 2025, including microbiological contamination and chemical exceedances, and inadequately designed and maintained that system with non-sanitary components including dead legs and threaded fittings; the firm's February 6, 2026 response lacked supporting documentation and sufficient corrective action plans. The FDA requires comprehensive remediation plans addressing out-of-specification investigation procedures, laboratory control oversight, and water system design, control, and maintenance.
Argus analysis
# FDA Warning Letter Analysis: Spa De Soleil, Inc.
**Company and Violations**
The FDA issued a warning letter to Spa De Soleil, Inc., a Sun Valley, California-based drug manufacturer, on July 8, 2026, following an inspection conducted January 20–26, 2026. The Center for Drug Evaluation and Research (CDER) identified significant Current Good Manufacturing Practice (CGMP) violations affecting over-the-counter topical drug products. The agency determined that the firm's manufacturing methods, facilities, and controls do not conform to CGMP requirements, rendering the drug products adulterated under the Federal Food, Drug, and Cosmetic Act.
**Regulatory Citations and Meaning**
The warning letter cites 21 CFR parts 210 and 211, which establish mandatory CGMP standards for pharmaceutical manufacturing. Specific violations include 21 CFR 211.192 (failure to investigate out-of-specification and out-of-limit test results) and 21 CFR 211.84(d)(1) and (d)(2) (inadequate component identity testing and supplier validation). The firm failed to properly investigate 51 microbiological and chemical failures in its water system from May 2024 through July 2025, instead resampling until achieving passing results without identifying root causes. Additionally, the firm failed to test incoming components—particularly those containing methanol, diethylene glycol, or ethylene glycol—for identity before use, creating potential safety hazards documented in FDA guidance.
**Response Timeline and Industry Implications**
The February 6, 2026 response was deemed inadequate; the firm must now submit a comprehensive remediation plan addressing water system design flaws, revised out-of-specification investigation procedures, supplier validation protocols, and a risk assessment for all distributed products. Compliance officers in the topical pharmaceutical sector should monitor whether Spa De Soleil issues customer notifications or product recalls, and whether the firm implements system validation studies. Future FDA actions may include import detention or facility closure if corrective actions remain insufficient.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Spa De Soleil, Inc. MARCS-CMS 728508 — July 08, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-100 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Ms. Rena Revivo Recipient Title Owner Spa De Soleil, Inc. 10443 Arminta Street Sun Valley , CA 91352-4109 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-100 July 8, 2026 Dear Ms. Revivo: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Spa De Soleil, Inc., FEI 3003876848, at 10443 Arminta Street, Sun Valley, from January 20 to 26, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 6, 2026 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP. During our inspection, our investigator observed specific violations including, but not limited to, the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). You failed to adequately investigate multiple microbiological out-of-limit (OOL) and chemical out-of-specification (OOS) results from testing the water you used to manufacture over-the-counter (OTC) (b)(4) drug products, including (b)(4) and (b)(4) . For example, from May 2024 through July 2025, you did not adequately investigate 51 OOL/OOS results from testing your (b)(4) . These included results for conductivity and total organic carbon testing that exceeded specifications, as well as the recovery of gram-negative microorganisms from multiple points of use. Your investigations did not include identification of the recovered microorganisms (e.g., genus, species). You resampled and retested the (b)(4) for microbiological quality to obtain passing results and continued to use the (b)(4) . Following an OOL recovery, you also placed certain point-of-use valves on hold until you obtained a passing result. However, this practice did not prevent you from using other valves on the same system. Microbiological recoveries from a (b)(4) system are not uniform, and results obtained at any point in the system can be an indicator of the quality of (b)(4) in…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "high" severity rating mean for this letter?
- High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Spa De Soleil, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Spa De Soleil, Inc. as of 2026-07-14. Argus ingests new FDA enforcement records daily.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Spa De Soleil, Inc. (2026-07-08) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-spa-de-soleil-inc-2026-07-08-cgmp
"Warning Letter Record: Spa De Soleil, Inc. (2026-07-08) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-spa-de-soleil-inc-2026-07-08-cgmp.
Argus HQ Research. "Warning Letter Record: Spa De Soleil, Inc. (2026-07-08) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-spa-de-soleil-inc-2026-07-08-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_spa_de_soleil_inc_2026_07_08_cgmp_2026,
title = {Warning Letter Record: Spa De Soleil, Inc. (2026-07-08) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-spa-de-soleil-inc-2026-07-08-cgmp},
note = {Accessed: July 15, 2026}
}